Publicaciones científicas

In vivo evaluation of a new embolic spherical particle (HepaSphere) in a kidney animal model

Esther de Luis (1), Jose I. Bilbao (1), Jose A. García Jalón de Ciércoles (2), Antonio Martínez-Cuesta (1), Alba de Martino Rodríguez (2) and María D. Lozano (3)
(1) Department of Radiology, Clínica Universitaria Navarra, Universidad de Navarra, Avda Pio XII 36, Pamplona, 31008, Navarra, Spain
(2) Animal Pathology Department, Veterinary Faculty, Universidad de Zaragoza, C/Miguel Servet 177, Zaragoza, 50013, Spain
(3) Pathology Department, Clínica Universitaria Navarra, Universidad de Navarra, Avda Pio XII 36, Pamplona, 31008, Navarra, Spain

Revista: CardioVascular and Interventional Radiology

Fecha: 01-mar-2008

Anatomía Patológica Radiología

HepaSphere is a new spherical embolic material developed in a dry state that absorbs fluids and adapts to the vessel wall, leaving no space between the particle and the arterial wall.

The aim of this study was to elucidate the final in vivo size, deformation, final location, and main properties of the particles when reconstituted with two different contrast media (Iodixanol and Ioxaglate) in an animal model. Two sizes of dry-state particles (50-100 and 150-200 microm) were reconstituted using both ionic and nonionic contrast media.

The mixture was used to partly embolize both kidneys in an animal model (14 pigs). The animals were sacrificed 4 weeks after the procedure and the samples processed. The final size of the particles was 230.2 +/- 62.5 microm for the 50- to 100-microm dry-state particles and 314.4 +/- 71 microm for the 150- to 200-microm dry-state particles. When the contrast medium (ionic versus nonionic) used for the reconstitution was studied to compare (Student's t-test) the final size of the particles, no differences were found (p > 0.05). The mean in vivo deformation for HepaSphere was 17.1% +/- 12.3%. No differences (p > 0.05) were found in the deformation of the particle regarding the dry-state size or the contrast medium (Mann-Whitney test).

We conclude that HepaSphere is stable, occludes perfectly, and morphologically adapts to the vessel lumen of the arteries embolized. There is no recanalization of the arteries 4 weeks after embolization. Its final in vivo size is predictable and the particle has the same properties in terms of size and deformation with the two different contrast media (Iodixanol and Ioxaglate).

CITA DEL ARTÍCULO Cardiovasc Intervent Radiol. 2008 Mar-Apr;31(2):367-76

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra